

Imatinib Mesylate Market in China 2021

<https://marketpublishers.com/r/I1AE86320F24EN.html>

Date: March 2021

Pages: 24

Price: US\$ 450.00 (Single User License)

ID: I1AE86320F24EN

Abstracts

The imatinib mesylate market in China in terms of revenue is set to grow by US\$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 22.9% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for imatinib mesylate. The China imatinib mesylate market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Hansoh Pharmaceutical Group Company Limited, Novartis International AG.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the imatinib mesylate market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China

Years Considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders

Get a comprehensive picture of the China imatinib mesylate market

Pinpoint growth sectors and trends for investment

Understand what the future of the imatinib mesylate market in China looks like

Identify the competitive landscape and window of opportunity

Contents

1. MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. MARKET DATA & OUTLOOK

3.1 Market Value

3.2 Market Value Forecast

4. IMATINIB MESYLATE MARKET BY REGION

4.1 Central South China

4.2 East China

4.3 North China

4.4 Northeast China

4.5 Northwest China

4.6 Southwest China

5. COMPANY PROFILES

5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

5.2 Hansoh Pharmaceutical Group Company Limited

5.3 Novartis International AG

6. APPENDIX

6.1 About StrategyHelix

6.2 Disclaimer

I would like to order

Product name: limatinib Mesylate Market in China 2021

Product link: <https://marketpublishers.com/r/l1AE86320F24EN.html>

Price: US\$ 450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l1AE86320F24EN.html>